Gland Pharma investors weighing 74% stake sale to Fosun in Alternative Plan
The shareholders of Gland Pharma Ltd, including buyout firm KKR and Co., are considering selling a stake of up to 74% under the automatic approval route to China’s Fosun International after failing to secure government approval for an 86% stake sale so far, two people aware of the discussions said. The new structure is being considered as an alternative, in…